Business
Mesoblast sees lasting need for COVID treatment beyond a vaccine – Sydney Morning Herald
The next two months will be hugely important for the stem cell therapy company’s research projects, and its growth prospects as it works on a product to treat the deadly disease.
Mesoblast is hoping its flagship product remestemcel-L will be shown to relieve acute respiratory distress syndrome (ARDS) in COVID-19 patients. The company is running a phase 3 trial of the product in US hospitals, but the research is still in its early stages, with a pilot study of the project looking at only 12 patients.
The US Data Safety Monitoring board, which reviews clinical data, had selected a date in early September to complete an initial review of Mesoblast’s phase 3 trial, the comp…
-
Noosa News22 hours agoDevastating update in search for missing Queensland mother Tayla Spies as police find human remains near her ute
-
Noosa News23 hours agoNicole Kidman Is Back in Wellness Guru Mode: ‘Nine Perfect Strangers’ Season Two Will Hit Your Streaming Queue in May
-
Business20 hours agoOwn the world with these 3 global ASX ETFs
-
General22 hours agoHousing affordability. The crisis the major parties are too scared to fix